Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

NCT01670084 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01670084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01670084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2012
Completion date
September 30, 2017
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell adult acute lymphoblastic leukemia, blastic phase chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, philadelphia chromosome positive adult precursor acute lymphoblastic leukemia, untreated adult acute lymphoblastic leukemia